Literature DB >> 12857376

No differences in colony formation of peripheral blood stem cells frozen with 5% or 10% dimethyl sulfoxide.

A M Bakken1, O Bruserud, J F Abrahamsen.   

Abstract

High-dose chemotherapy with autologous stem cell rescue usually requires cryopreservation of the cells. For several years, 10% dimethyl sulfoxide (DMSO) has been used as the standard cryoprotectant. Because DMSO infusion can lead to toxic clinical complications in a dose-related manner, we wanted to evaluate if reduction to 5% DMSO would be possible. We have compared colony formation in the myeloid, erythropoietic, and megakaryocyte lineages in peripheral blood progenitor cell (PBPC) samples cryopreserved in parallel with 5% and 10% DMSO. Twenty-seven PBPC samples from patients with malignant diseases were investigated after 3 months of cryopreservation in liquid N(2), and samples from 14 of these patients were investigated after 1 year. A significantly higher colony formation was demonstrated for colony-forming units-erythrocyte (CFU-E) and CFU-granulocyte, erythrocyte, macrophage, megakaryocyte (GEMM) both at 3 months and at 1 year in the 5% samples. For CFU-granulocyte-macrophage (GM) and CFU-megakaryocyte (Mk) no significant difference was demonstrated neither at 3 months nor at 1 year in samples frozen with 5% and 10% DMSO. Also, there was a statistically significant correlation between the CFU-total and CFU-Mk-total, indicating that the CFU-total might be used as an evaluation of megakaryocyte progenitors. Viability testing with the Trypan Blue exclusion test showed that cells cryopreserved in 5% DMSO had significantly higher viability than the cells cryopreserved in 10% DMSO. We conclude that 5% DMSO is at least as good for cryopreservation of small-volume PBPC samples as the conventional 10% DMSO, and our results suggest that the possibility of using 5% DMSO for cryopreservation of autologous PBPC grafts should be further investigated in clinical studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12857376     DOI: 10.1089/152581603322023089

Source DB:  PubMed          Journal:  J Hematother Stem Cell Res        ISSN: 1525-8165


  7 in total

Review 1.  Cryopreservation of hematopoietic stem cells.

Authors:  David Berz; Elise M McCormack; Eric S Winer; Gerald A Colvin; Peter J Quesenberry
Journal:  Am J Hematol       Date:  2007-06       Impact factor: 10.047

2.  Clinical grade adult stem cell banking.

Authors:  Sreedhar Thirumala; W Scott Goebel; Erik J Woods
Journal:  Organogenesis       Date:  2009-07       Impact factor: 2.500

Review 3.  Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion.

Authors:  Z Shu; S Heimfeld; D Gao
Journal:  Bone Marrow Transplant       Date:  2013-09-30       Impact factor: 5.483

4.  Evaluation of methylcellulose and dimethyl sulfoxide as the cryoprotectants in a serum-free freezing media for cryopreservation of adipose-derived adult stem cells.

Authors:  Sreedhar Thirumala; Jeffrey M Gimble; Ram V Devireddy
Journal:  Stem Cells Dev       Date:  2010-04       Impact factor: 3.272

5.  Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation - a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients.

Authors:  Ida Marie Rundgren; Elisabeth Ersvær; Aymen Bushra Ahmed; Anita Ryningen; Øystein Bruserud
Journal:  BMC Immunol       Date:  2019-11-08       Impact factor: 3.615

6.  Optimization of Human Peripheral Blood Mononuclear Cells (PBMCs) Cryopreservation.

Authors:  Robab Nazarpour; Ebrahim Zabihi; Ebrahim Alijanpour; Zeinab Abedian; Hamid Mehdizadeh; Fatemeh Rahimi
Journal:  Int J Mol Cell Med       Date:  2012

7.  Towards Reduction or Substitution of Cytotoxic DMSO in Biobanking of Functional Bioengineered Megakaryocytes.

Authors:  Denys Pogozhykh; Dorothee Eicke; Oleksandr Gryshkov; Willem F Wolkers; Kai Schulze; Carlos A Guzmán; Rainer Blasczyk; Constança Figueiredo
Journal:  Int J Mol Sci       Date:  2020-10-16       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.